In­no­Care IPO over­sub­scribed 300x as Hong Kong in­vestors turned to biotech amid runoff

For­get the glob­al stock melt­down. Or at least Chi­nese biotech In­no­Care did, forg­ing ahead with a more than $250-mil­lion IPO in Hong Kong de­spite …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.